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Abstract
Continuous-flow left ventricular assist devices (CF-LVAD) are now providing years of safe circulatory support with
enhanced quality of life. We present four cases of patients with advanced heart failure who received support for
greater than 5-years with the HeartMate II CF-LVAD. One patient continues with support at 7.5 years and has
decided to not undergo cardiac transplantation. Another patient has also had LVAD support for 7.7 years, initially
with a pulsatile flow LVAD, and then was switched to the HeartMate II, which has continued to support him for the
last 6.6 years. Two other patients have undergone heart transplant after support times of 5.46 years and 5.75 years.
Few complications occurred and the patients had very active lifestyles during support. Explant analysis revealed
very low bearing wear and minimal pannus.
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Background
The durations of support with implantable mechanical
circulatory support devices have increased in recent
years with the introduction of continuous-flow left ven-
tricular assist devices (CF-LVAD). Safer long-term sup-
port has been achieved because of improved device
durability and an overall reduction in life-threatening
complications [1]. Improved outcomes achieved over the
past decade have increased the confidence of physicians
and patients for longer durations of CF-LVAD support.
[2] Transplant candidates can wait safely for extended
durations while their status at transplant is optimized,
aiding post-transplant survival. Patients supported for
destination therapy who remain free of serious compli-
cations can live for many years with active lifestyles and
an acceptable quality of life [3]. In this report, we de-
scribe four cases in which patients with active lifestyles
were supported with CF-LVAD for over 5 years.
Method
A systematic, retrospective review of patient data was car-
ried out. All patients who were on support by HeartMate
2 for more than five years were considered for this paper.
Electronic medical records were reviewed hospital course,
for outcome and complications.
Results
Case 1
A 46-year-old male with ischemic cardiomyopathy was
presented with worsening heart failure symptoms and
underwent implantation of a HeartMate II CF-LVAD
(Thoratec Corporation, Pleasanton, CA, USA) for tempor-
ary support until transplant. The postoperative recovery
was uneventful, and the patient was discharged from the
hospital 23 days after the implant. He resumed an active
life style and rehospitalization was only for exchange of a
defibrillator battery. Acquired von Willebrand syndrome
and hemolysis were observed approximately one year after
implant and were treated by a slight reduction in anticoa-
gulation therapy and intravenous Haemate P (coagulation
factor VIII). The patient is followed at regular outpatient
clinic visits at approximately 2-month intervals. The
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device pump speed is maintained at 9400 to 9600 RPM
and the estimated pump flow is approximately 5.0 L/min.
Phenprocoumon (Coumarin) dose is adjusted to achieve
an international normalized ratio (INR) of approximately
2.5, and the patient takes 75 mg clopidogrel daily. There
have been no problems related to LVAD equipment main-
tenance. The driveline exit site has been free from infec-
tion for the duration of his circulatory support (Fig. 1).
This patient has decided to not undergo heart trans-
plant, he exercises at a gym twice a week and works as
an office supervisor, and support continues 7.63 years
after implantation.
Case 2
A 56-year-old male with dilated cardiomyopathy pre-
sented in October 2005 with NYHA class IV symptoms,
pulmonary hypertension, and right heart failure. A pul-
satile-flow HeartMate I (XVE-LVAD) was implanted and
supported the patient for 13 months until a motor failure,
which required the LVAD to be replaced with a HeartMate
II device in November 2006. Postoperatively, right heart
failure required inotropic support and mechanical ventila-
tion for 10 days. Other postoperative complications in-
cluded atrial fibrillation, multiple hematomas at the
driveline exit site, acquired von Willebrand syndrome, dia-
betes, knee arthritis and chronic renal insufficiency. The
patient left the intensive care unit after 12 days and was
discharged from the hospital on postoperative day 49.
Since discharge, the patient has required care for ascites,
renal insufficiency, and thrombosis of the right jugular
vein. The patient is currently receiving dialysis. Although
the patient has had multiple complications (unrelated to
the device), he has enjoyed an active life during his
7.70 years of mechanical circulatory support, including
currently 6.60 years on the HeartMate II CF LVAD. He is
retired, and tends to gardening as a hobby.
Case 3
A 23-year-old male diagnosed with dilated cardiomyop-
athy presented with acute decompensated heart failure
and was being treated with high-dose dobutamine. Due to
worsening renal and hepatic function, a HeartMate II was
implanted as a bridge to transplant. Upon anesthesia in-
duction, the patient experienced a cardiac arrest, which
was promptly treated with cardiopulmonary resuscitation
(CPR) and then cardiopulmonary bypass. The LVAD was
implanted in the usual manner, and a MEDOS HIA VAD
(MEDOS Medizintechnik AG, Stolberg, Germany) tem-
porary right ventricular assist device (RVAD) was also im-
planted due to intermittent right heart failure. Renal
failure with dialysis, postoperative bleeding that required
surgical reexploration, hepatic dysfunction and cardiac
arrhythmias complicated the postoperative course. After
4 days of RVAD support the device was removed. On post-
operative day 17, the patient experienced ventricular fibril-
lation that was treated with defibrillation and implantation
of an implantable cardioverter defibrillator (ICD). Recov-
ery was gradual, dialysis and mechanical ventilation were
weaned, and the patient was transferred from the intensive
care unit on postoperative day 94. After complete rehabili-
tation, the patient was discharged from the hospital and
Fig. 1 The driveline exit site in patient 1 after 7.5 years of support
Fig. 2 The inlet bearing ball (a) and cup (b) explanted from the
patient in case 3 after 5.46 years of LVAD support are free of
accumulated thrombus and demonstrate low bearing wear
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lived an active life without serious complications. On
December 19, 2010, after 5.46 years of LVAD support, the
patient underwent successful heart transplant. Analysis of
the explanted LVAD (Fig. 2) showed a clean pump with no
accumulated thrombus and very low bearing wear of
0.381 μm over 5.46 years (.070 μm/year) consistent with
estimated bearing life of well over 17 years of support as
previously reported [4]. In addition, the outflow conduit is
clean and without pannus formation in the outflow con-
duit (Fig. 3).
Case 4
A 21-year-old male with dilated cardiomyopathy expe-
rienced acute decompensation that was treated by im-
plantation of a HeartMate II LVAD. Postoperatively,
the patient experienced hemorrhagic bronchitis, pneu-
monia, pulmonary hypertension, gastritis, and hepatitis
that eventually resolved with therapy. After complete
recovery and rehabilitation, the patient was discharged
from the hospital on postoperative day 23. The patient
has had elevated lactate dehydrogenase (LDH) in the
range of 400 to 1000 IU/L, but clinically significant
device thrombosis has not been detected with careful
monitoring. The LVAD is maintained at a speed of 9600
RPM, and the average calculated flow rate is 4.6 L/min.
The patient had a very active lifestyle while on LVAD sup-
port including regular participation in sports (cycling,
soccer). The patient experienced a fractured humerus that
occurred during a sporting activity, which was repaired
and has healed. Due to the patient’s high activity level, a
wire within the external portion of the driveline fractured
and required repair. After 5.75 years of LVAD support, the
patient underwent successful heart transplant. He con-
tinues to actively participate in sports at a fitness center
and plays soccer on a German amateur team. Explant ana-
lysis showed the pump free of accumulated thrombus and
with low bearing wear of 1.163 um over 5.75 years (.202
um/yr.), consistent with findings from case 2.
Discussion
These cases demonstrate that safe long-term mechanical
circulatory support exceeding five years is achievable
with today’s technology. This provides options that were
not available a few years ago for advanced heart failure
patients where heart transplantation is not possible or
desirable. The HeartMate II axial-flow LVAD with a sin-
gle moving component, the impeller, has been demon-
strated to be very durable in more than 14,000 implants
worldwide. In our experience, the HeartMate II is an
extremely reliable LVAD system, which has been dem-
onstrated by our stable and low incidence of pump
thrombosis over many years [5].
Extended support exceeding 5 years with the HeartMate
II has not been previously described in scientific publica-
tions, but there are over 120 patients being supported for
over 5 years with the longest now reaching over 8 years
according to the company’s registry. There have been no
reports of mechanical pump bearing or motor failure with
the HeartMate II.
On the basis of our experience, the key to successful
long-term destination therapy is a structured outpatient
clinic, which tremendously helps to avoid life-threatening
complications. Careful monitoring of anticoagulation ther-
apy is essential to avoid thrombotic and hemorrhagic
complications. Meticulous driveline care and stabilization
minimizes infectious problems. ICD implantation and
routine monitoring of electrolytes with treatment control
arrhythmias. Complete rehabilitation, good nutrition, and
exercise aid in avoiding complications. Finally, patient
monitoring for problems and an appropriate response
plan aids in prompt resolution of problems.
Conclusion
The HeartMate II CF-LVAD has excellent clinical durabil-
ity for over 5 years to provide long-term hemodynamic
support options for patients with advanced heart failure.
Comprehensive patient education, vigilant outpatient care
and thorough monitoring to avoid adverse events are im-
portant contributions to safe long-term support.
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Fig. 3 The absence of pannus in the interior of the outflow elbow
explanted from the patient in case 3 after 5.46 years of LVAD support
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